The randomized phase II study EA2142 is one of the first prospective trials conducted for patients with advanced, high-grade (G3) non-small cell gastroenteropancreatic neuroendocrine neoplasms. The trial found that temozolomide and capecitabine (CAPTEM) chemotherapy was not superior to standard chemotherapy (platinum and etoposide) as a front-line treatment for these patients—even though CAPTEM demonstrated a more favorable toxicity profile.

In this video, study chair Jennifer R. Eads, MD (University of Pennsylvania, Abramson Cancer Center) discusses the relevance of the findings, which she presented at the 2022 Annual Meeting of the American Society of Clinical Oncology.